

SCAAR


Real-life clinical outcomes with the use of Orsiro in Sweden: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Conclusions

- In this large, nationwide, retrospective analysis Orsiro[®] is associated with a significantly lower risk of Target Lesion Revascularization (TLR) compared to other modern n-DES*.
- Orsiro shows numerically lower rates of In-Stent Restenosis (ISR) and definite Stent Thrombosis (ST) compared to other modern n-DES.
- These results emphasize the potential incremental clinical benefits of Orsiro's ultrathin strut during Percutaneous Coronary Intervention (PCI).

Study design

Nationwide, retrospective, multicentre, observational registry recording all PCI procedures in Sweden between 2011-2017.



Endpoints

Clinical endpoints


- All-cause Death, Myocardial Infarction (MI), Definite ST, ISR, TLR by PCI out to 2 years

| Patient characteristics ¹ | Orsiro n = 4,561 | n-DES n = 69,570 | SMD** |
|--------------------------------------|---------------------|---------------------|-------|
| Age years, (SD)‡ | 67.2 ± 11.1 | 67.8 ± 10.9 | 0.049 |
| Male | 74.1% | 73.7% | 0.008 |
| Diabetes | 22.1% | 21.4% | 0.018 |
| Hypertension | 62.9% | 61.5% | 0.029 |
| Previous MI | 22.1% | 21.0% | 0.027 |
| Previous PCI | 17.1% | 17.8% | 0.019 |
| Clinical indication | | | |
| Stable CAD | 20.4% | 20.8% | 0.049 |
| Unstable CAD | 9.7% | 9.9% | 0.049 |
| NSTEMI | 38.7% | 39.7% | 0.049 |
| STEMI | 28.5% | 26.6% | 0.049 |


| Lesion characteristics ¹ | Orsiro n = 4,561 | n-DES n = 69,570 | SMD |
|-------------------------------------|---------------------|---------------------|-------|
| B2/C | 65.6% | 61.6% | 0.084 |
| Bifurcation | 19.0% | 18.7% | 0.008 |
| 3VD/LM | 20.3% | 23.1% | 0.067 |

* n-DES: Xience Family, Resolute Family, Promus Family, Synergy, and Ultimaster > 1000 implantations;
 ** SMD: Standardized Mean Difference, value >0.1 may indicate statistically significant differences.²
 ‡ Data shown as mean ± SD

TLR rate by PCI out to 2 years¹



ISR rate out to 2 years¹



Definite ST rate out to 2 years¹



Clinical outcomes out to 2 years¹

| Clinical Endpoint | Adjusted HR (95% CI) Orsiro vs. n-DES | p-value |
|-------------------|--|---------|
| TLR | 0.75 [0.60-0.94] | 0.013 |
| All-cause Death | 0.99 [0.72-1.35] | 0.94 |
| MI | 1.19 [0.99-1.43] | 0.06 |
| ISR | 0.81 [0.63-1.03] | 0.09 |
| DST | 0.90 [0.55-1.46] | 0.66 |

1. Sergio B et al. Real-life clinical outcomes with the use of an ultrathin sirolimus-eluting stent in Sweden: A report from the Swedish coronary angiography and angioplasty registry; Presented at EuroPCR 2019; May, 2019; 2. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation. 2009 May 14;38(6):1228-34.

Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies. Xience is a trademark of Abbott Cardiovascular Systems Inc.; Resolute and Integrity are registered trademarks of Medtronic Vascular Inc.; PROMUS and PROMUS PREMIER are trademarks or registered trademarks of the Boston Scientific Group of Companies; Synergy is a registered trademark of Boston Scientific. Ultimaster is a trademark or registered trademark of the Terumo Group of companies.